<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-91e9c5c4=""><div class="content_outer_container" data-v-91e9c5c4=""><div class="share_preview_container" data-v-91e9c5c4=""><div class="dialog_list" data-v-91e9c5c4=""><div class="dialog_item" data-v-91e9c5c4=""><div class="dialog_question fir_dialog_question" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""><h1 class="fir_question_content" data-v-91e9c5c4="">
                                    Is salarius pharma getting any new funding
                                </h1> <div class="user_slot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-91e9c5c4=""> <span class="user_desction" data-v-91e9c5c4="">
                                        
                                        8/1/2024 09:08am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-91e9c5c4="">Yes, Salarius Pharmaceuticals has received new funding. The company recently closed a private placement for the issuance and sale of shares of its common stock and accompanying warrants, raising approximately $6 million in gross proceeds. Additionally, Salarius has received a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT) for the development of seclidemstat. These funds will be used for further development of the company's product candidates and working capital.</div> <div class="dialog_answer" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""> <div class="answer_robot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/AIme.ae832fb.png" alt="robot" class="avatar" data-v-91e9c5c4=""> <div class="user_name" data-v-91e9c5c4=""></div></div> <div class="question_content" data-v-91e9c5c4=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-4e97ba8a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-4e97ba8a=""> <div class="recommend-part" data-v-7790c618="" data-v-4e97ba8a=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:r,comeFrom:"AInvestShareLink",events:e,answerSource:k}],fetch:{},error:e,state:{sharePreviewModule:{loadJgySuccess:0,dialogRenderList:[{originAnswer:{input_media_info:[],agent_id:a,output_media_info:[],task_id:a,source:k,reply_action:"Answer",execute_mode:s,param:"{\"trace_id\":\"20003020172247450065300000000774\",\"question\":\"Is salarius pharma getting any new funding\",\"user_id\":\"1801997110\",\"user_name\":\"\",\"input_type\":\"typewrite\",\"session_id\":\"f344d3a32c6ee4af75d34790ea46a3c4\",\"source\":\"ths_wencai_international\"}",agent_info:[{info_type:t,title:u,full_summary:"HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it has closed its previously announced private placement for the issuance and sale of an aggregate of 3,636,364 shares of its common stock (or common stock equivalents in lieu thereof), Series A-1 warrants to purchase up to an aggregate of 3,636,364 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 3,636,364 shares of common stock at a purchase price of $1.65 per share (or common stock equivalent) and accompanying warrants, priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. The Series A-1 warrants have an exercise price of $1.40 per share, are exercisable immediately upon issuance and have a term of five and one-half years from the date of issuance. The Series A-2 warrants have an exercise price of $1.40 per share, are exercisable immediately upon issuance and have a term of 18 months from the date of issuance. The gross proceeds to the Company from the private placement were approximately $6 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the private placement for further development of its product candidates and working capital and general corporate purposes. The securities offered in the private placement and described above were offered in a transaction not involving a public offering under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and\u002For Rule 506(b) of Regulation D promulgated thereunder and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities in the private placement may not be reoffered or resold in the United States except pursuant to an effective registration statement with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file an initial registration statement with the SEC covering the resale of the securities to be issued in the private placement no later than 15 days following the date of the agreement. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Salarius Pharmaceuticals Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius’ product portfolio includes seclidemstat, Salarius’ lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader. Seclidemstat has received fast track, orphan drug and rare pediatric disease designations for Ewing sarcoma from the U.S. Food and Drug Administration and is currently in a Phase 1\u002F2 clinical trial for relapsed\u002Frefractory Ewing sarcoma. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with an investigator-initiated Phase 1\u002F2 clinical study in hematologic cancers at MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing program and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). SP-3164 is curr",summary:v,url:w,image_url:a,video_url:a,publish_time:"2024-07-11"},{info_type:t,title:x,full_summary:"HOUSTON , Feb. 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc . (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the receipt of a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT). The payment is part of a non-dilutive grant of approximately $16.1 million awarded to Salarius to support its operations and development of its drug candidate seclidemstat for the treatment of Ewing sarcoma. This $1.48 million payment brings Salarius’ cumulative disbursement from CPRIT to approximately $16.0 million . “CPRIT has been an exceptional source of non-dilutive funding for Salarius and we are grateful for the support shown by the State of Texas to Salarius and other development-stage companies working in oncology,” said David Arthur , president and chief executive officer. “We recently reported encouraging interim data demonstrating that first- and second-relapse Ewing sarcoma patients treated with seclidemstat in combination with topotecan and cyclophosphamide who achieve disease control may have a longer time until tumor progression when compared to patients treated with topotecan and cyclophosphamide alone. The CPRIT grant helps fund this trial.” “Although our Phase 1\u002F2 sarcoma clinical trial with seclidemstat is on partial clinical hold owing to a suspected unexpected severe adverse reaction in the FET-rearranged arm, not the Ewing sarcoma arm, we are hopeful to receive permission from the U.S. Food and Drug Administration to resume enrollment in the Ewing arm of the trial in the coming months,” Mr. Arthur added. To date, CPRIT has awarded over $3 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs. It has also recruited more than 285 distinguished researchers to Texas , supported the establishment, expansion or relocation of 52 companies to Texas , and generated over $7.6 billion in additional public and private investment. Salarius was awarded a product development research grant in May 2016 for the development of seclidemstat, and the disbursements are based upon Salarius’ achievement of defined goals and objectives. Under the grant agreement, Salarius must provide matching funds equal to 50% of the CPRIT funding and make a good faith effort to spend at least half of the CPRIT grant and matching monies with Texas -based employees, contractors and service providers. About Salarius Pharmaceuticals Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius’ product portfolio includes seclidemstat, Salarius’ lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader. Seclidemstat is currently in a Phase 1\u002F2 clinical trial for relapsed\u002Frefractory Ewing sarcoma and certain additional sarcomas that share a similar biology. This trial is currently on a partial clinical hold and is not enrolling new patients. Seclidemstat has received fast track, orphan drug and rare pediatric disease designations for Ewing sarcoma from the U.S. Food and Drug Administration . Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with an investigator-initiated Phase 1\u002F2 clinical study in hematologic cancers at MD Anderson Cancer Center . This trial is currently on a partial clinical hold and is not enrolling new patients. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing program and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). SP-3164 is c",summary:y,url:z,image_url:a,video_url:a,publish_time:"2024-07-30"}],answer_chain_name:"agent_common_v2\nagent-summary",come_from:a,text_answer:r,trace_id:A,cost:12598,question:d,input_type:"typewrite",fall_back_reason:{fallback_type:a,risk_detail:{matched_words:[]}},session_id:B,first_return_cost:5046,transfer_question:d,start_time:C,remote_svc:"jgateway",slots:[],answer_type:s,user_id:l,skill_name:D},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",base_info:{trace_id:A,session_id:B,user_id:l,question:d,source:k,raw_question:d,version:"3.3.3"},extra:{}},{answer_path:h,section:{id:i,info_texts:["Thinking"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},extra:{}},{answer_path:h,section:{id:i,info_texts:["Searching Web : Salarius Pharma funding"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},extra:{}},{answer_path:h,section:{id:i,info_texts:["Generating Answer"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},extra:{}},{answer_path:f,section:{id:m,info_texts:[],show_type:g,voice_txt:"Yes",text_answer:E,rich_text:E,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:f,section:{id:F,info_texts:[],show_type:g,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:w,title:u,summary:v,index:3}],is_last:b},extra:{}},{answer_path:f,section:{id:m,info_texts:[],show_type:g,voice_txt:". Additionally",text_answer:G,rich_text:G,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:f,section:{id:F,info_texts:[],show_type:g,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:z,title:x,summary:y,index:4}],is_last:b},extra:{}},{answer_path:f,section:{id:m,info_texts:[],show_type:g,voice_txt:". These",text_answer:H,rich_text:H,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:h,section:{id:i,info_texts:["Completed"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:I,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10001,info_texts:[],show_type:I,choice:[{display_text:n,query_text:n,trace_info:{item_id:"c34f9bce3fabdc91d1e464314d7ac967",item_type:o,item_name:n,rec_info:"0+416_351_21_130+0+0+20003020172247450065300000000774+c34f9bce3fabdc91d1e464314d7ac967+llm_generated+aimeTagAnalysis+0+onLineLGBM+1"}},{display_text:p,query_text:p,trace_info:{item_id:"3e50af3079cd672bf7c72467f2bb13b0",item_type:o,item_name:p,rec_info:"0+416_351_21_130+0+0+20003020172247450065300000000774+3e50af3079cd672bf7c72467f2bb13b0+llm_generated+aimeTagAnalysis+0+onLineLGBM+2"}},{display_text:q,query_text:q,trace_info:{item_id:"888747a62c499a66bf5514103bab0d6b",item_type:o,item_name:q,rec_info:"0+416_351_21_130+0+0+20003020172247450065300000000774+888747a62c499a66bf5514103bab0d6b+llm_generated+aimeTagAnalysis+0+onLineLGBM+3"}}],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:"signal",choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{action_name:D,with_paid_index:c,no_refresh_answer:c},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:e,docsData:[],quoteData:e},tplType:"question"},events:void 0,agentId:a}],userId:l,userName:a,startTime:C,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:e,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],traceTableData:e,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002F",config:{_app:{basePath:J,assetsPath:J,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"Is salarius pharma getting any new funding",null,"other\u002FopenAnswer","rich_text","progress\u002Fsearching_for",1000,"searching_for","ths_wencai_international","1801997110",2001,"How has the company's stock price performed over the past year?","llm_generated","What is the current market capitalization of Salarius Pharma?","What are the key factors that have influenced the company's stock price in the past?","Yes, Salarius Pharmaceuticals has received new funding. The company recently closed a private placement for the issuance and sale of shares of its common stock and accompanying warrants, raising approximately $6 million in gross proceeds. Additionally, Salarius has received a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT) for the development of seclidemstat. These funds will be used for further development of the company's product candidates and working capital.","agent","search","Salarius Pharmaceuticals Announces Closing of $6 Million ...","The Company currently intends to use the net proceeds from the private placement for further development of its product candidates and working ...","https:\u002F\u002Finvestors.salariuspharma.com\u002Fnews-releases\u002Fnews-release-details\u002Fsalarius-pharmaceuticals-announces-closing-6-million-private","Salarius Pharmaceuticals Receives $1.48 Million from the ...","Salarius was awarded a product development research grant in May 2016 for the development of seclidemstat, and the disbursements are based upon ...","https:\u002F\u002Finvestors.salariuspharma.com\u002Fnews-releases\u002Fnews-release-details\u002Fsalarius-pharmaceuticals-receives-148-million-cancer-prevention","20003020172247450065300000000774","f344d3a32c6ee4af75d34790ea46a3c4",1722474500658,"review stocks","Yes, Salarius Pharmaceuticals has received new funding. The company recently closed a private placement for the issuance and sale of shares of its common stock and accompanying warrants, raising approximately $6 million in gross proceeds[^3]",2000,". Additionally, Salarius has received a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT) for the development of seclidemstat[^4]",". These funds will be used for further development of the company's product candidates and working capital.","choice","\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/195837b.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/e402278.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7c15041.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/69a864a.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/9579193.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/6726d3c.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/c69ce63.js" defer=""></script>